eucrisa™
crisaborole ointment 2%

APPLY ANYWHERE ON AFFECTED SKIN

OF PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS[1]

Not for ophthalmic, oral, or intravaginal use.

EUCRISA is the first and only topical PDE-4 inhibitor indicated for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.[1*]

PDE-4=phosphodiesterase-4.
* Comparative clinical significance unknown.

CONSIDER EUCRISA AS PART OF YOUR TREATMENT PLAN FOR MILD TO MODERATE ATOPIC DERMATITIS

Apply a thin layer of ointment **twice daily** to cover any affected areas of skin.

- 2x — Apply topically twice daily
- Ages 2 and up
- Anywhere on affected skin

Relevant warnings and precautions

- Hypersensitivity reactions, including contact urticaria
- Use in pregnant and nursing women
- Use in geriatric patients

For more information

Consult the Product Monograph at http://pfizer.ca/pm/en/Eucrisa.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.

References: 1. EUCRISA Product Monograph. Pfizer Canada ULC. June 11, 2018. **2.** Paller A, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol* 2016;75(3):494–503.

eucrisa™
crisaborole ointment 2%

MEMBER OF INNOVATIVE MEDICINES CANADA PAAB

Pfizer
YOUR PARTNER IN DERMATOLOGY

PHOTOS FROM THE PIVOTAL TRIALS DEPICTING SUCCESS IN ISGA SCORE AT DAY 29[1,2†]



- **Significantly more EUCRISA patients (31.4%) achieved success in ISGA** (a score of Clear [0] or Almost Clear [1] with at least a 2-grade improvement from baseline) vs. vehicle (18%) at Day 29 ($p<0.001$)
- **48.5% of EUCRISA patients achieved an ISGA of Clear (0) or Almost Clear (1)** vs. 29.7% of vehicle patients at Day 29 ($p<0.001$; 2° endpoint)

Actual case, individual results may vary. May not be representative of results in the general population.

† Results from a multicentre, randomized, double-blind, parallel-group, vehicle-controlled trial of patients aged 2 to 79 years of age (mean age was 12.6 in the EUCRISA group and 11.8 in the vehicle group) with a 5% to 95% treatable body surface area (baseline mean was 17.9% in the EUCRISA group and 17.7% in the vehicle group). Patients were randomized 2:1 to receive EUCRISA (n=513) or vehicle (n=250) applied twice daily for 28 days.

PROVEN SAFETY AND TOLERABILITY PROFILE[1]

APPLICATION SITE PAIN‡ WAS THE MOST COMMON ADVERSE REACTION (≥1%) DURING THE 4-WEEK PIVOTAL TRIALS

EUCRISA (n=1012)	Proprietary vehicle ointment (n=499)
4.45% (n=45)	**1.20%** (n=6)

Adapted from EUCRISA Product Monograph.

In the 48-week, open-label, single-arm, long-term safety study:§

- The most frequent adverse events reported in EUCRISA patients treated intermittently were atopic dermatitis, application site pain‡, and application site infection

‡ Application site pain refers to skin sensations such as burning or stinging.

§ 517 patients 2 to 72 years of age (including 454 patients 2 to 17 years of age), who had completed one of the Phase 3 studies without safety issues that precluded further treatment, were treated with EUCRISA twice daily intermittently for up to 48 weeks in 28-day on-treatment or off-treatment cycles.

eucrisa™
crisaborole ointment 2%